FDA rejects Amarin appeal on Vascepa trial design, shares slump

January 21, 2014 1:56 PM

36 0

FDA rejects Amarin appeal on Vascepa trial design, shares slump

(Reuters) - Amarin Corp Plc's shares fell more than 25 percent in premarket trading after U.S. health regulators rejected a preset testing process as the company seeks broader use of its blood fat-lowering drug.

The Irish drugmaker said it planned to appeal the decision, but that it does not expect a decision on the extended use of the drug while the appeal is pending.

Read more

To category page

Loading...